SCHEMBL2428611

SCHEMBL2428611

CC(=O)c1ccc(-c2nc3ccc(Br)cc3s2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 5/20 0.63
KDM4E B2RXH2 3/20 0.56
NFKB1 P19838 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
LMNA P02545 1/20 0.56
RAB9A P51151 5/20 0.56
NPC1 O15118 4/20 0.56
MAPT P10636 3/20 0.56
GAA P10253 2/20 0.56
MITF O75030 1/20 0.56
ALDH1A1 P00352 1/20 0.56
POLB P06746 1/20 0.56
HPGD P15428 1/20 0.56
RECQL P46063 1/20 0.56
GFER P55789 1/20 0.56
PAX8 Q06710 1/20 0.56
KLF5 Q13887 1/20 0.56
TDP1 Q9NUW8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31120302 0.83 APP (0.81) APPKDM4ESMN1; SMN2RAB9ANPC1
SCHEMBL7600496 0.83 KDM4E (0.56) APPKDM4ENFKB1NFKB2RELA
SCHEMBL7602093 0.82 HDAC6 (0.57) APPKDM4ENFKB1NFKB2RELA
SCHEMBL4806067 0.81 APP (0.72) APPKDM4ESMN1; SMN2LMNARAB9A
SCHEMBL14415813 0.81 KDM4E (0.80) APPKDM4ENFKB1NFKB2RELA
SCHEMBL2432602 0.80 APP (0.59) APPKDM4ENFKB1NFKB2RELA
SCHEMBL2432605 0.80 APP (0.59) APPKDM4ENFKB1NFKB2RELA
SCHEMBL121577 0.80 KDM4E (0.81) KDM4ENFKB1NFKB2RELASMN1; SMN2
SCHEMBL23169620 0.80 RAB9A (0.64) APPKDM4ENFKB1NFKB2RELA
SCHEMBL13932580 0.79 DYRK1A (0.57) APPKDM4ENFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 US disclosed
EP-1956013-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION Fujifilm RI Pharma Co., Ltd. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION APP, TTR, BACE1 APP 1/4885KDM4E 3451/4885NFKB1 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.